OMEGA

Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update

Retrieved on: 
Thursday, March 28, 2024
HCC, Research, Epigenomics, Toxicity, Obesity, Cell death, Growth, Burns, Gene expression, Novo Nordisk, NSCLC, AASLD, Appetite, OMEGA, DCR, Patient, Lung, Tissue, Cohort, CXCL9, CXCL10, Omega, G&A, Cancer, Messenger, Lung cancer, Human, Life expectancy, Liver regeneration, DLT, Fibrosis, Thermogenesis, Therapy, MYC, Liver, Pharmacokinetics, Hepatitis, CXCL11, LNP, Pharmaceutical industry

Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.

Key Points: 
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $15.5 million, compared to $26.0 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $6.2 million, compared to $5.7 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $20.2 million, compared to $30.8 million for the fourth quarter of 2022.
  • The decrease in net loss for 2023 compared to 2022 was primarily due to decreases in R&D expenses.

Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya

Retrieved on: 
Tuesday, March 12, 2024
Food, General Electric, IGI, Organization, OMEGA, Business, Executive, Cornell University, Boy, Sale, Rutgers University, Clinical trial, Therapy, DRL, Fortune 500

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.

Key Points: 
  • NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Intrommune Therapeutics , Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board of directors.
  • “We are delighted to welcome Hem Pandya as the Executive Chairperson of Intrommune’s Board of Directors and Dr. Jon Rich as a board member,” said Michael Nelson, CEO, Intrommune Therapeutics.
  • I look forward to supporting the development of Intrommune’s demonstrated safe and convenient food allergy therapies,” said Hem Pandya.
  • Along with serving as Executive Chairman for Intrommune, Mr. Pandya currently serves on the Board of Directors for Exchange Health, LLC, Senores Pharmaceuticals and on the Board of Advisors for Anodyne Nanotech, Inc.

STARMUS UNVEILS ITS PROGRAM FOR "STARMUS VII, THE FUTURE OF OUR HOME PLANET" IN BRATISLAVA

Retrieved on: 
Wednesday, March 20, 2024
Universe, Communication, Climate change, Gene editing, KIA, University, Environment, Science, OMEGA, Partnership, Astronaut, Artificial intelligence, Jane Goodall Institute, The Offspring, STAR, AI, Doctor of Philosophy, Star party, Future, European Commission, Planet, Science communication, Entertainment

The festival will kick off with a soon-to-be-announced legendary artist performance followed by a week-long event at the Ice Hockey Stadium, Ondrej Nepela Arena.

Key Points: 
  • The festival will kick off with a soon-to-be-announced legendary artist performance followed by a week-long event at the Ice Hockey Stadium, Ondrej Nepela Arena.
  • 108' Round Table – Starmus most exclusive round table with eminent panellists will conclude the day.
  • Throughout the event, the STARMUS Camp and City Program in collaboration with Slovak universities will be held in Hlavné námestie with science exhibitions, presentations, and a vibrant music program.
  • STARMUS VII will be held under the auspices of the President of the Slovak Republic and the Mayor of Bratislava and under the patronage of the European Commission Representation in Slovakia.

STARMUS UNVEILS ITS PROGRAM FOR "STARMUS VII, THE FUTURE OF OUR HOME PLANET" IN BRATISLAVA

Retrieved on: 
Wednesday, March 20, 2024
Universe, Communication, Climate change, Gene editing, KIA, University, Environment, Science, OMEGA, Partnership, Astronaut, Artificial intelligence, Jane Goodall Institute, The Offspring, STAR, AI, Doctor of Philosophy, Star party, Future, European Commission, Planet, Science communication, Entertainment

The festival will kick off with a soon-to-be-announced legendary artist performance followed by a week-long event at the Ice Hockey Stadium, Ondrej Nepela Arena.

Key Points: 
  • The festival will kick off with a soon-to-be-announced legendary artist performance followed by a week-long event at the Ice Hockey Stadium, Ondrej Nepela Arena.
  • 108' Round Table – Starmus most exclusive round table with eminent panellists will conclude the day.
  • Throughout the event, the STARMUS Camp and City Program in collaboration with Slovak universities will be held in Hlavné námestie with science exhibitions, presentations, and a vibrant music program.
  • STARMUS VII will be held under the auspices of the President of the Slovak Republic and the Mayor of Bratislava and under the patronage of the European Commission Representation in Slovakia.

11 MoonSwatch Suitcases Are Sold at Sotheby's, Raising Over $600K for Orbis

Retrieved on: 
Tuesday, February 27, 2024
OMEGA, Hospital, CHF, Sotheby, MoonSwatch, Orbis International, Patient, MD-10, Sotheby's, Auction

This generous gift from OMEGA will contribute to Orbis's mission to build strong and sustainable eye care systems.

Key Points: 
  • This generous gift from OMEGA will contribute to Orbis's mission to build strong and sustainable eye care systems.
  • "I am incredibly grateful to OMEGA and their continued support of Orbis," said Derek Hodkey, President and CEO of Orbis International.
  • I even had the privilege to view one of the beautiful suitcases on display at the OMEGA store in New York City.
  • Orbis thanks OMEGA and everyone who took part in the auction and appreciates the great interest shown in the support of Orbis.

11 MoonSwatch Moonshine Gold suitcases to be auctioned at Sotheby's by OMEGA for Orbis

Retrieved on: 
Thursday, February 1, 2024
Boutique, Sotheby's, Hospital, OMEGA, Patient, MoonSwatch, Collection, Aviation, Planet, Orbis International, Omega Speedmaster, Gold, Auction

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Eye care nonprofit Orbis International announces it will receive 100% of the proceeds from 11 MoonSwatch Moonshine Gold suitcases being auctioned by long-term partner OMEGA through Sotheby's from February 12th to 24th.

Key Points: 
  • NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Eye care nonprofit Orbis International announces it will receive 100% of the proceeds from 11 MoonSwatch Moonshine Gold suitcases being auctioned by long-term partner OMEGA through Sotheby's from February 12th to 24th.
  • Each suitcase contains all of the 11 OMEGA x Swatch "Mission to Moonshine Gold" timepieces.
  • Before the auction takes place, the 11 "Mission to Moonshine Gold" suitcases will go on display at 11 OMEGA Boutiques around the world from February 1st to 11th, including Boutiques in Zurich, Tokyo, Bangkok, Singapore, Hong Kong, Beijing, New York, London, Milan, Paris and Sydney.
  • These 11 watches each feature a seconds hand coated in 18K Moonshine™ Gold – a distinctive alloy created in-house at OMEGA that offers a more subtle and long-lasting form of yellow gold.

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Retrieved on: 
Thursday, January 4, 2024
Biology, Ecosystem, Flagship, Partnership, Drug discovery, Risk, Research, Thermogenesis, Chemistry, Disease, Flagship Pioneering, Tissue, Pharming, Therapy, Novo Nordisk, AI, Appetite, Gene expression, Chronic liver disease, Obesity, Transplant, DSM-IV codes, Liver failure, OMEGA, Liver disease, Thermoregulation, Cardiovascular disease, Intelligence, Medicine, Pharmaceutical industry

4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company.

Key Points: 
  • 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) and Cellarity Inc. today announced that Novo Nordisk has entered into separate research collaborations with each company.
  • These are the first two programmes signed under the framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.
  • “Novo Nordisk is committed to advancing new treatment options for people living with cardiometabolic diseases.
  • In September 2022, Novo Nordisk engaged Cellarity to identify novel cell behaviors implicated in MASH disease progression.

Cadence Partners with Antiviral Discovery Consortium to Spearhead Rapid Development of Treatments for Viral Pandemics

Retrieved on: 
Thursday, December 7, 2023
Technology, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, ACT, Diamond, Pandemic, Computational chemistry, Trust, ASAP, COVID Moonshot, Weizmann Institute of Science, OpenEye Scientific Software, Drug, Moonshot, Environmental Molecular Sciences Laboratory, Artificial intelligence, Protogygia postera, Diamond Light Source, Machine learning, Therapy, NIH, Drug discovery, Human, OMEGA, Wellcome, Doctor of Philosophy, Pi, Orion, MSKCC, Cadence Design Systems, Pharmaceutical industry

Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.

Key Points: 
  • Cadence Molecular Sciences (OpenEye)—a business unit of Cadence Design Systems (Nasdaq: CDNS)—will provide OpenEye’s molecular design software to power the open-science AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium in support of an innovative effort to rapidly develop antivirals to prevent future pandemics.
  • Chodera and the ASAP scientists working with him will have access to OpenEye tools to help support the ASAP Discovery Consortium and antiviral drug research,” said Anthony Nicholls, PhD, corporate vice president, OpenEye, Cadence Molecular Sciences.
  • “Open-science drug discovery against future pandemics is an essential public service,” said Chodera.
  • The ASAP Discovery Consortium is led by PIs John Chodera (MSKCC), Alpha Lee (PostEra) and Peter Sjö (DNDi).

Nautilus and UNESCO Present A Special Ocean Programme at the Phillip and Patricia Frost Museum of Science and Art Basel Miami Beach

Retrieved on: 
Tuesday, November 21, 2023
Island, Painting, Philip, Bertarelli Foundation, The Nautilus (magazine), Schmidt Ocean Institute, Hope, ART, Creativity, Beauty, Intergovernmental Oceanographic Commission, Collection, Art Basel, Miami Beach Convention Center, Museum, Biodiversity, Partnership, Human, Exhibition, Sustainability, OMEGA, United Nations, Knowledge, Phillip Frost, UNESCO, Interior design, Tourism, Fashion design, Nautilus, Science, MIAMI, Vikings

MIAMI, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Nautilus Magazine, UNESCO and the Phillip and Patricia Frost Museum of Science will unveil a dynamic program of ocean-themed exhibitions during the renowned Art Basel Miami Beach from December 6-10, 2023. Celebrating the UN Decade of Ocean Science for Sustainable Development 2021-2030, the purpose of the program is to raise awareness, inspire action on ocean conservation, and foster a deeper understanding of the intricate connection between humanity and the marine environment.

Key Points: 
  • MIAMI, Nov. 21, 2023 /PRNewswire-PRWeb/ -- Nautilus Magazine, UNESCO and the Phillip and Patricia Frost Museum of Science will unveil a dynamic program of ocean-themed exhibitions during the renowned Art Basel Miami Beach from December 6-10, 2023.
  • "By weaving together the worlds of art and science, we hope to captivate and educate the diverse audience that Art Basel Miami Beach attracts," stated Nautilus Publisher, John Steele.
  • "Frost Science is thrilled to unveil this special ocean science exhibition during Miami Art Week.
  • The exhibition will be hosted at Frost Science and Art Basel Miami Beach at the Miami Beach Convention Center.

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, HCC, NSCLC, AACR, Rheumatism, American Association for the Study of Liver Diseases, OMEGA, IND, International, Therapy, Hepatology, Flagship Pioneering, Liver regeneration, G&A, Investigational New Drug, Conference, Palatine Nos. 1–8, 21, Fibrosis, Dive (Belgian band), MYC, Hepatitis, R, Pharmacokinetics, Acute respiratory distress syndrome, Omega, Epigenomics, Lung, Tissue, Annual report, Messenger, LNP, Institutional review board, Inflammation, Lung cancer, Hepatocellular carcinoma, Cancer, Patient, Gene expression, AASLD, Management, Pharmaceutical industry, Vaccine, Dietary supplement

As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.

Key Points: 
  • As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
  • Research and development (R&D) expenses for the third quarter of 2023 were $16.5 million, compared to $20.7 million for the third quarter of 2022.
  • General and administrative (G&A) expenses for the third quarter of 2023 were $7.9 million, compared to $5.2 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $22.2 million, compared to $25.8 million for the third quarter of 2022, driven predominantly by a decrease in R&D expenses.